Lecrosine

Sodium cromoglicate, the active ingredient in Lecrosine, is a mast cell stabilizer presented as an ophthalmic solution for ocular use. It helps control allergic inflammation of the eye in patients with seasonal or vernal allergic conjunctivitis. GNH USA supplies Lecrosine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecrosine, a mast cell stabilizer, is used to manage ocular allergic conditions by preventing mast‑cell degranulation. - Allergic conjunctivitis: reduces redness, itching and watery discharge caused by seasonal allergens. - Vernal keratoconjunctivitis: helps control chronic inflammation and photophobia in patients with this severe form of allergic eye disease. - Seasonal allergic conjunctivitis: provides prophylactic relief during high pollen periods, decreasing symptom severity.

Adverse reactions to ocular sodium cromoglicate are generally mild and related to the formulation.

Common Side Effects: - Transient burning or stinging sensation upon instillation. - Mild ocular irritation or foreign‑body sensation. - Temporary blurred vision that resolves quickly. - Conjunctival hyperemia (redness). - Tearing or increased lacrimation.

Serious or Rare Side Effects: - Persistent ocular irritation lasting more than 24 hours. - Development of corneal epithelial defects. - Severe allergic reaction to preservative components. - Vision loss unrelated to underlying disease. - Secondary ocular infection.

When using Lecrosine, consider the following safety measures. - Avoid contact with the tip of the bottle to prevent contamination. - Do not use if the solution appears discoloured or contains particles. - Discontinue if severe irritation or allergic reaction occurs and consult a healthcare professional. - Use only as prescribed; do not exceed the recommended frequency. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lecrosine may interact with other ocular medications or systemic agents that affect mast‑cell function.

Major Interactions (Avoid): - Concurrent use of other mast‑cell stabilisers may increase local irritation. - Co‑administration with topical antihistamines containing preservatives that can cause additive ocular surface toxicity.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids may alter the inflammatory response, requiring monitoring of symptom control. - Use with contact lenses may reduce drug efficacy; advise removal before instillation. - Concomitant use of ocular antibiotics may mask signs of infection; monitor for infection signs.